Importantly, after blocking CD94, the remaining population of CD8bright cells recognizing HLA-E/BZLF1 was significantly higher in MS-RR patients when compared with HC (p≤0.01) (Fig. 4F). This evidence concerns the gene HLA-E and myeloid sarcoma.